Explore how GLP-1 agonists, originally for diabetes, could transform addiction treatment by reducing cravings.
FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...
Snack foods and sweet treats have seen a decline in purchases, as people reach for more nutrient-dense options.
We recently compiled a list of the Top 10 AI Stocks Dominating Wall Street. In this article, we are going to take a look at ...
With with GLP-1 drugs, gastrointestinal issues, such as nausea, vomiting, constipation, and gastroesophageal reflux disease, ...
Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...
Cedars-Sinai experts are advocating for patients to have access to GLP-1 medications such as semaglutide as a key component to caring for and preventing cardiovascular disease.
In line with trial results, real-world data suggest GLP-1 receptor agonists have certain benefits in patients with moderate to severe chronic kidney disease (CKD).
The study of more than two million veterans with diabetes details GLP-1 RA use relating to 175 outcomes; without ...
A large study published in Nature Medicine reviewed the effects of GLP-1 drugs like Ozempic and Mounjaro on 175 different ...
Oprah Winfrey says taking a GLP-1 drug such as Ozempic and Wegovy has changed her entire perspective on “thin people.” The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback